Australia markets closed

  • ALL ORDS

    7,042.70
    +102.10 (+1.47%)
     

  • AUD/USD

    0.7757
    +0.0046 (+0.60%)
     

  • ASX 200

    6,789.60
    +116.30 (+1.74%)
     

  • OIL

    62.49
    +0.99 (+1.61%)
     

  • GOLD

    1,749.30
    +20.50 (+1.19%)
     

  • BTC-AUD

    59,758.88
    +851.46 (+1.45%)
     

  • CMC Crypto 200

    926.13
    -7.01 (-0.75%)
     
✉️ Free sign-up:

Get the news straight to your inbox every day.

Stay in the loop every day with Yahoo Finance's free Fully Briefed newsletter.

Ray Allen on the athlete's voice, recalls Heat bringing awareness to Trayvon Martin

The 18-year NBA veteran spoke with Yahoo Sports senior NBA insider Chris Haynes as part of Verizon's Next20 series about the next generation of sports activism.

Latest stories

  • Chinese Conglomerate’s $2.3 Billion Share Sale Raises Concerns for Inter Milan

    (Bloomberg) -- The decision by embattled Chinese conglomerate Suning Appliance Group Co. to shut down a soccer club in its hometown of Jiangsu is raising concerns that the next to get entangled in the indebted company’s efforts to raise cash could be its prize asset in Italy, FC Internazionale Milano SpA.In a bid to ease debt payment pressure, the appliance retailer said Sunday that state-owned Shenzhen International Holdings Ltd. and Shenzhen Kunpeng Equity Investment Management Co. planned to purchase 8% and 15% of Suning.com.’s shares, respectively, paying a total of 14.8 billion yuan ($2.3 billion). Jiangsu Football Club, owned by Suning since 2015, said over the weekend that it would cease operations, without elaborating. Suning.com Co., the key listed unit, jumped by the daily limit of 10% after shares resumed trading Monday in Shenzhen.The halt of the Chinese soccer club’s operations adds to uncertainty over the future of Inter Milan. Suning acquired 70% of Inter Milan in 2016 for 270 million euros ($306 million at the time). The company has since expanded its soccer empire, including a $650 million deal by digital broadcaster PPTV -- a unit of Suning Holdings Co. -- for a three-year television contract with England’s Premier League.“Chinese conglomerates were growing through acquisitions due to cheap funding. Now that the good old time is over, it makes sense to refocus on core businesses,” said Warut Promboon, managing partner at credit research firm Bondcritic Ltd. “The key is not about being leaner but being more focused on what they can do best. And for Suning, it is about the retail business, not football clubs, in our view.”Suning said Sunday that the introduction of state-owned investors will help the company further focus on its retail business. Analysts expect the company to divest more non-retail assets as it re-focuses, which could include selling off its 70% stake of Inter Milan. The company on Monday declined to comment further on the stake sale.Cash CrunchConcerns about the retail giant’s financial health have been growing since last year, when online talk of a cash crunch pressured bonds issued by Suning.com, the key listed unit -- chatter Suning Appliance at the time dismissed as “rumor.” The pressure on Suning comes at a time when other Chinese conglomerates are in full retreat as Beijing moves to rein in financial risk.It’s also another blow to China’s billionaires, which includes Suning’s founder Zhang Jindong, as officials move to more closely regulate their flamboyant overseas purchases that have included cinema chains, historic buildings and sports clubs.What Is Behind China’s Crackdown on Its Tech Giants: QuickTakeBoth Suning.com and its parent face high near-term repayment pressure, according to China Chengxin International Rating Co. A combined 15.8 billion yuan of bonds will be payable this year for the two firms when they are confronting refinancing difficulties, Chengxin said in a report earlier this month.In a recent sign of liquidity strain, Suning Appliance conducted a swap offer for a yuan bond due Feb. 2. A majority of the holders agreed to exchange the 7.3% note for a new two-year bond carrying the same coupon. In January, Suning Appliance said it pledged 376.5 million shares, or a 4.04% stake, in Suning.com to China Minsheng Banking Corp. to raise funds.Helping EvergrandeSuning Appliance’s debt risk has also come under further focus after it helped China Evergrande Group avoid a cash crunch by deciding not to demand repayment of a 20 billion yuan strategic investment in the indebted developer. Suning is an Evergrande supplier, and a collapse could have had ripple effects on its business.“The non state-owned conglomerates are set to focus more on their main businesses amid the challenging business environment and improve their profitability and efficiency in order to better compete with global rivals,” said Bruce Pang, head of macro research at China Renaissance Securities Hong Kong.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Huawei exec's extradition fight enters final round in Canada

    The high-stakes battle by Chinese Huawei Technologies executive Meng Wanzhou against extradition to the United States enters its final stage in a Canadian court on Monday, after more than two years of legal skirmishes and diplomatic barbs.

  • Eurofins Announces the launch of an At-Home COVID-19 PCR Test kit available direct to consumers, without prescription

    Eurofins’s Clinical Enterprise, Inc. announces that it has received US Food and Drug Administration Emergency Use Authorization (EUA) for a direct-to-consumer (DTC) version of its EmpowerDX COVID-19 Home Collection Kit.

  • Oil Pushes Higher as Critical OPEC+ Meeting Looms, Dollar Eases

    (Bloomberg) -- Oil demonstrated its resilience in the week’s opening session, rebounding from the biggest slump since November ahead of a key OPEC+ meeting that may see some supply returned to a fast-tightening market.Futures in New York rose toward $63 a barrel after losing 3.2% on Friday. The alliance gathers on Thursday and is expected to return some barrels after prices got off to their best ever start to a year. But it’s unclear how robustly the group will act, with the Saudi Arabian energy minister calling for producers to remain “extremely cautious.” A weaker dollar also supported crude.See also: OPEC+ Faces Calls to Cool Oil Market Frenzy With Extra BarrelsOil’s recovery from the impact of the pandemic has been driven by Asian demand, as well as fiscal and monetary stimulus. Data Monday showed most key manufacturing economies gained ground last month, with China staying in expansionary territory. In the U.S., President Joe Biden’s $1.9 trillion relief plan moved closer to realization after passing the House of Representatives.Saudi Arabia’s reductions, the improving demand outlook as vaccines are rolled out, and the growing popularity of commodities as a hedge against inflation have pushed oil higher this year. There has been a raft of bullish calls in recent weeks predicting the rally will continue as the producer response trails consumption, while maintenance in North Sea fields is set to reduce supply.“The OPEC+ meeting is very important,” said Michael McCarthy, chief markets strategist at CMC Markets Asia Pacific. The “market could remain easily positive in the face of a modest increase in OPEC+ production. If there is a large increase, then it could dampen the outlook in the short term,” he said.At stake in the meeting is how much OPEC+ output gets restored and how fast, with current reductions amounting to just over 7 million barrels a day, or 7% of global supply. The 23-nation coalition will decide whether to revive a 500,000-barrel tranche in April, and in addition, whether the Saudis confirm an extra 1 million barrels they’ve taken offline will return as scheduled.Brent’s prompt timespread was 72 cents a barrel in backwardation, a bullish structure with near-dated prices above later-dated ones. That compares with 25 cents at the start of February and a discount at the beginning of the year.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Beijing using Covid-19 to obstruct foreign journalists: media group

    China is using the Covid-19 pandemic as "yet another way to control journalists", a press group said Monday, warning that Beijing has introduced extra surveillance and restrictions for health reasons as tools to frustrate reporters' work.

  • Outrage after champion trainer's dead horse photo emerges

    An Irish horse trainer is being investigated over a disturbing images that surfaced online over the weekend.

  • 'Inferior' women: China counters Uighur criticism with explicit PR attacks

    China, under growing global pressure over its treatment of a Muslim minority in its far west, is mounting an unprecedented and aggressive campaign to push back, including explicit attacks on women who have made claims of abuse. As allegations of human rights violations in Xinjiang mount, with a growing number of Western lawmakers accusing China of genocide, Beijing is focussing on discrediting the female Uighur witnesses behind recent reports of abuse. The officials said the information was evidence of bad character, invalidating the women's accounts of abuse in Xinjiang.

  • Bonds Gain; Asian Stocks, U.S. Futures Advance: Markets Wrap

    (Bloomberg) -- Sovereign bonds extended a rebound, U.S. and European equity futures rose and the dollar dipped Monday, signaling calmer markets after the turmoil sparked by last week’s slide in government debt.Treasury benchmark yields fluctuated around 1.40% and Australian and New Zealand debt rallied sharply. Australia’s 10-year yield slid the most in a year after the central bank doubled purchases at its regular bond-buying operation in a fresh bid to pacify fixed-income markets.The recovery in bonds helped S&P 500 and Nasdaq 100 equity futures advance, while stocks in Japan, Australia and Hong Kong jumped. On Friday, the S&P 500 slipped and tech stocks staged a modest rebound as Treasuries recovered from their sharpest selloff in a year.Most Group-of-10 currencies climbed, with the Australian and New Zealand dollars among the outperformers despite data showing China’s economic recovery slowed in February. Commodities rose as oil topped $62 a barrel.“With a lot of the move in yields due to the improving growth outlook and reopening prospects, risk appetite is holding up,” said Esty Dwek, head of global strategy at Natixis Investment Manager Solutions. “The pace and scale of the move in yields is more important than the absolute level, suggesting that as long as the move is gradual, risk assets should be able to absorb them.”Global bonds have stabilized and equity markets edged higher after central banks from Asia to Europe provided reassurance that policy support remains in place. Investors have become concerned about the prospect of higher inflation leading to tighter policy as the global recovery gathers pace, and traders are ramping up positioning for the Federal Reserve to start raising interest rates as soon as next year.“The market is testing the Fed and global central banks as to how serious they are here,” Al Lord, Lexerd Capital Management chief executive officer, said on Bloomberg TV. “There are growth expectations and growing inflation concerns, and that’s playing out in the markets.”Over the weekend, the U.S. House of Representatives passed President Joe Biden’s $1.9 trillion Covid-19 aid package. The bill heads to the Senate, where Biden will need to woo Republican support or avoid losing a single Democratic vote.There are some key events to watch this week:Reserve Bank of Australia sets monetary policy Tuesday.U.S. Federal Reserve Beige Book is due Wednesday.OPEC+ meeting on output Thursday.Fed Chair Jerome Powell to discuss the economy at a Wall Street Journal event on Thursday.The February U.S. employment report on Friday will provide an update on the speed and direction of the nation’s labor market recovery.These are some of the main moves in markets:StocksS&P 500 futures rose 0.7% as of 6 a.m. in London. The S&P 500 Index fell 0.5%.Japan’s Topix index gained 2%.Australia’s S&P/ASX 200 index rose 1.7%.Hong Kong’s Hang Seng Index climbed 1.3%.Euro Stoxx 50 contracts jumped 0.9%.CurrenciesThe yen traded at 106.55 per dollar.The offshore yuan was at 6.4679 per dollar, up 0.2%.The Bloomberg Dollar Spot Index fell 0.3%.The euro was at $1.2083.The Aussie dollar rose 0.6% to 77.54 U.S. cents.BondsAustralia’s 10-year yield fell 25 basis points to 1.67%.The yield on 10-year Treasuries was steady at about 1.40%.CommoditiesWest Texas Intermediate crude rose 1.5% to $62.39 a barrel.Gold rose 1% to $1,750.27 an ounce.(An earlier version of this story corrected a mention about metals.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • From U.S. domination to energy transition, two years that changed oil

    Former U.S. Secretary of State Mike Pompeo took the stage at the world's largest energy conference in 2019 to declare an age of U.S. dominance after a decade of rapid shale development made the United States the world's top oil and gas producer. Two years later, the oil industry is recovering from the worst recession it has ever experienced after measures to contain coronavirus stopped billions of people from traveling and wiped out one-fifth of worldwide demand for fuel. The U.S. fossil fuel industry is still reeling after tens of thousands of jobs were lost.

  • FOREX-Risk currencies recover from Friday carnage as bonds regain composure

    * Dollar hits six-month high against the yen * Sterling rises on bets of vaccine-led economic rebound * Australian dollar, kiwi dollar, Canadian dollar bounce * Graphic: World FX rates https://tmsnrt.rs/2RBWI5E (Adds comments, details on sterling, bitcoin) By Kevin Buckland and Sagarika Jaisinghani TOKYO, March 1 (Reuters) - The Australian dollar and other riskier currencies rebounded against the U.S. dollar on Monday, as a sell-off last week in global bonds on worries about eventual monetary policy tightening appeared to have eased for now. "The market is overpricing (the chance of a near-term rate hike)," said Tohru Sasaki, JPMorgan's head of Japan market research in Tokyo.

  • No more jail for setting friend on fire

    A man who doused a friend in petrol and set her alight will not serve any more jail time after a Brisbane judge found mental health a key factor in his offending.The behaviour of Matt James Nolan, 30 was described as "robotic" when he arrived at the north Brisbane home where Sigourney Coles was sleeping in July 2017.

  • 230 allege abuse by NH youth center staffers

    Abuse allegations against New Hampshire’s state-run youth detention center have grown to include 230 men and women who say they were physically or sexually abused as children by 150 staffers between 1963 and 2018. (March 1)

  • P.E. teacher navigates pandemic with charity’s aid

    Schools have struggled to help kids maintain an active lifestyle during the pandemic. And P.E. teachers have an extra challenge adapting their classes for remote learning (March 1)

  • Idorsia submits NDA for clazosentan to Japanese PMDA

    Allschwil, Switzerland – March 1, 2021 Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). The application is supported by replicated results from the Japanese registration program which consisted of two double-blind, randomized, placebo-controlled studies assessing the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality events in adult Japanese patients following aSAH. Patients were randomized to receive continuous infusion of either 10 mg/hr clazosentan or placebo for up to 15 days following the onset of aSAH. The two studies followed the same design, with one enrolling 221 patients whose aneurysm was secured by surgical clipping and the other enrolling 221 patients whose aneurysm was secured by endovascular coiling. Satoshi Tanaka, Dr Med Sci. and President of Idorsia Pharmaceuticals Japan, commented:“The development of clazosentan has taken many years to bring us to the filing of an NDA and we were very fortunate to not be held back by the COVID-19 pandemic in Japan. The team has worked rapidly to analyze the data and prepare the dossier for the PMDA so that we can bring clazosentan to the patients as soon as possible. We will now work together with the authorities through the regulatory process, and in parallel, prepare the scientific publication and the commercial launch which we hope to see in the first half of 2022.” Both studies showed that clazosentan reduced the occurrence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH with statistical significance (p<0.01 for both studies). The composite endpoint was defined by at least one of the following: All death / New cerebral infarction due to cerebral vasospasm / Delayed ischemic neurologic deficit due to cerebral vasospasm and adjudicated blindly by an independent committee. The effect of clazosentan on all-cause morbidity and mortality was also significant (p<0.05) in a pre-planned analysis of the pooled studies whereas a numerical trend was observed in each study on this endpoint. The studies confirmed the well-documented safety profile of clazosentan which has now been administered to approximately 2000 patients around the world. In these registration studies in Japanese patients post-aSAH there were no unexpected safety findings. Treatment-emergent adverse events occurring in >5% of the clazosentan group (with a difference of >2% compared to placebo) were vomiting and signs of hemodilution or fluid retention (i.e., hyponatremia, hypoalbuminemia, anemia, pleural effusion, brain and pulmonary edema). Notes to the editor Available data in Japanese patientsA Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan administered by continuous intravenous infusion significantly reduced vasospasm and vasospasm-related morbidity and mortality events. The results are published in Cerebrovascular Diseases (Fujimura M, et al. Cerebrovasc Dis 2017;44:59–67). On that basis, a registration program was initiated with clazosentan in Japan in May 2016. About the global registration program “REACT”In February 2019, Idorsia initiated REACT, a prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH. The Phase 3 study builds upon the learnings from the previous clazosentan studies to identify patients at high risk of vasospasm and delayed cerebral ischemia, the optimal dose, the best measure to demonstrate efficacy and an optimized patient management guideline to ensure patient safety. Approximately 400 patients – treated either with microsurgical clipping or endovascular coiling – are being enrolled at approximately 95 sites across 15 countries. Patients are randomized to receive continuous infusion of either clazosentan (15 mg/hr) or placebo prophylactically, on top of local standard of care, for a period of up to 14 days. REACT is enrolling aSAH patients identified as being at high risk of developing vasospasm and subsequent delayed cerebral ischemia because of high-volume hemorrhage, as assessed by CT scan on hospital admission. Patients experiencing asymptomatic cerebral vasospasm, as measured by angiography, within 14 days of aSAH may also be included. Results of the study are targeted for the second half of 2022. About aneurysmal subarachnoid hemorrhage and cerebral vasospasmAneurysmal subarachnoid hemorrhage is a rare condition involving sudden life-threatening bleeding occurring in the subarachnoid space. It is caused by the rupture of an aneurysm – a weak, bulging spot on the wall of a cerebral artery. Emergency surgical repair (endovascular coiling or microsurgical clipping) is required to stop the hemorrhage. The bleeding and the release of a vasoconstrictor (endothelin) by the neighboring vascular endothelium can lead to cerebral vasospasm (constriction of arteries in the brain), usually occurring between 4 and 14 days after aneurysm securing. This diminishes blood flow to the brain, and about one third of patients consequently experience worsening of their neurological condition. Cerebral vasospasm is one of the leading secondary causes of disability and death in patients with aSAH. The incidence of aSAH is estimated to be between 6 and 9 per 100,000 per year worldwide. Notably, aSAH is a significant problem in Japan, with an incidence at least twice as high as in many other countries of the world. Approximately 50% of the overall aSAH population present with thick, diffuse blood clots characterized by a large amount of subarachnoid blood on the admission CT scan. These patients have a significantly higher risk of experiencing cerebral vasospasm. Available clinical data with clazosentanSeveral studies have built our understanding of the role of clazosentan in preventing or reversing cerebral vasospasm. In 2006, results were reported for clazosentan in the prevention of angiographic vasospasm in patients with aSAH. The Phase 2 dose-finding study, CONSCIOUS-1, demonstrated dose-dependent prevention of vasospasm. This was followed by two Phase 3 studies, CONSCIOUS-2 and CONSCIOUS-3, to assess the effect of clazosentan on the incidence of cerebral vasospasm-related morbidity and all-cause mortality. In 2010, CONSCIOUS-2 showed that the 5 mg/h dose of clazosentan, administered by continuous intravenous infusion, did not allow a statistically significant treatment effect to be observed, resulting in the premature termination of CONSCIOUS-3. However, an exploratory analysis of the data collected in CONSCIOUS-3 showed that a higher dose of clazosentan (15 mg/h), administered by continuous intravenous infusion, significantly reduced cerebral vasospasm-related morbidity and all-cause mortality, with a 44% relative risk reduction (p=0.0074). The 15 mg/h dose also significantly reduced the incidence of delayed ischemic neurological deficit, with a 54% relative risk reduction (p=0.0038). In addition, clazosentan reduced the need for rescue therapy for vasospasm. Clazosentan did not improve long-term clinical outcome. A Phase 2 study in Japanese and Korean patients showed that 10 mg/hr of clazosentan significantly reduced vasospasm and vasospasm-related morbidity and mortality events. A pilot study evaluating the early effect of clazosentan on reversing established cerebral vasospasm in large proximal cerebral artery segments at 3 hours post initiation suggests that, with early administration, clazosentan has the potential to improve large-vessel vasospasm. In a post-hoc analysis of the effect of clazosentan on reversing established cerebral vasospasm in the entire cerebral vasculature (including smaller distal vessel segments and the cerebellar arteries), a clearly visible improvement was observed in vessel diameter at 3 and 24 hours. The studies confirmed the well-documented safety profile of clazosentan, which has now been administered to approximately 2000 patients around the world. The side effects of clazosentan are managed based on clear protocol guidelines: hypotension can be mitigated using blood pressure control with vasopressors in the ICU, while lung complications (such as pulmonary edema) can be managed by aiming to maintain euvolemia by avoiding excessive fluid administration. Key literatureFujimura M, et al. Cerebrovasc Dis 2017; 44:59–67Macdonald R L, et al. Stroke. 2012; 43(6):1463-9.Macdonald R L, et al. The Lancet. Neurology, 2011; 10(7):618-625.Macdonald R L, et al. Stroke 2008; 39:3015-3021.Vajkoczy P, et al. Journal of Neurosurgery 2005; 103:9-17.Roux S. et al. J Pharmacol Exp Ther 1997; 283:1110-1118.Clozel M, Watanabe H, Life Sciences 1993; 52(9):825-834 About IdorsiaIdorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets. About Idorsia Pharmaceuticals JapanIdorsia Pharmaceuticals Japan was established, under the leadership of Dr Satoshi Tanaka, in 2018 to conduct clinical development and prepare the commercialization of Idorsia's innovative and promising compounds for patients in Japan. For further information, please contactAndrew C. WeissSenior Vice President, Head of Investor Relations & Corporate CommunicationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.commedia.relations@idorsia.com www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

  • Arcadis finds U.S., Singapore, and Japan most attractive places to build data centers

    Amsterdam, March 1, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced the release of its Data Center Location Index 2021, which lists the most favorable markets for localization. Following the United States, Singapore and Japan, Sweden and Norway took the fourth and fifth spots, respectively. The Arcadis Data Center Location Index 2021 includes 50 markets across six continents ranking optimal places to build data centers in the world. The index is based on each market’s performance across eight key criteria: GDP per capita, dealing with construction permits, price of electricity, energy security, cybersecurity, domestic market size, the number of mobile broadband subscriptions and mean download speed. Using the above-mentioned criteria, Arcadis data specialists divided these into supply and demand criteria and then both were combined with equal weighting (50/50). The individual criteria weightings were determined based on their assessment of the relative importance of each factor. Weightings are set so that all factors have a material effect on the final index ranking. The final index value is a sum of weighted scores which have been collated from publicly available sources. The purpose of the index is to provide insights that can be used to guide the decision-making process about where to establish a new facility. Selecting the best location is a critical factor that helps determine how well a data center investment will perform, as well as making sure the undertaking will be resilient and sustainable in a particular community. Additionally, the report outlines a roadmap for the process of building a new data center and commentary on the significant current issues impacting the industry including climate change, the effects of COVID-19, and the growth of hyperscalers. Arcadis partners with clients across the entire data center construction process, delivering due diligence, project management, cost management, design, stakeholder engagement, and digital capabilities to help companies optimize the planning, building, operations and maintenance of a new facility. “Arcadis has the global scale and expertise to help accelerate the building of data center infrastructure that supports our digital lives. We help clients make the best location choices and other decisions that result in a solid, sustainable investment that benefits all stakeholders including the community,” says Peter Oosterveer, Arcadis CEO. “Our lives are increasingly moving online, leading to a surge in data creation and consumption. This, in turn, requires us to build a resilient and growing infrastructure. While each project will ultimately depend on a unique combination of factors, this index is meant to provide a starting point to help clients think through the decision criteria influencing the optimal location.” says Natalie Sauber, Arcadis UK Market Intelligence Lead. -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT:ARCADIS CORPORATE COMMUNICATIONSMonika GrabekMobile: +31 6 11 40 36 96E-mail: monika.grabek@arcadis.com ARCADIS INVESTOR RELATIONSJurgen PullensMobile: +31 6 51599483E-mail: jurgen.pullens@arcadis.com ABOUT ARCADIS Arcadis is the leading global Design & Consultancy organization for natural and built assets. Applying our deep market sector insights and collective design, consultancy, engineering, project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 28,000 people, active in over 70 countries that generate €3.5 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com Attachment Arcadis finds U.S., Singapore, and Japan most attractive places to build data centers

  • Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

    Pratteln, Switzerland, March 1, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces positive results from its multiple ascending dose Phase 1b study with lonodelestat, a potent inhibitor of human neutrophil elastase (hNE), in patients with cystic fibrosis (CF). Lonodelestat is a potent and selective peptide inhibitor of human neutrophil elastase (hNE), currently being developed in cystic fibrosis (CF). Neutrophil elastase is an enzyme associated with tissue inflammation, leading to degradation of the lung tissue in cystic fibrosis and several other pulmonary diseases. Data from previous Phase 1a studies demonstrated that single dose inhalation of lonodelestat can lead to high drug concentrations within sputum, resulting in effective hNE inhibition [1, 2]. The double-blind, placebo-controlled dose-escalation Phase 1b study in patients with CF assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple daily doses of lonodelestat for up to four weeks (clinicaltrials.gov id: NCT03748199). In addition, the study investigated proof of mechanism of lonodelestat by measuring activity of hNE, an inflammatory biomarker for monitoring of disease progression in CF. Santhera acknowledges the support of the Cystic Fibrosis Foundation (CFF) by providing funding for the conduct of the Phase 1a and 1b safety trials with lonodelestat. A total of 32 patients were randomized in four cohorts of eight patients each and received lonodelestat starting with 80 mg once daily (QD), 80 mg twice daily (BID), 160 mg QD, each administered for 15 days, followed by a last cohort with 40 mg QD administered for 28 days which was chosen after observing an effect on forced expiratory volume in 1 second (FEV1) in some patients treated with the highest doses (80 mg BID and 160 mg QD). In all four cohorts and over all treatment durations, lonodelestat demonstrated a good tolerability and no serious side effects (SAEs or AEs Grade 3 or higher) were reported by the patients. Results showed a linear dose-exposure relationship over the dose range from 40 mg to 160 mg, with no accumulation in plasma or sputum. In all cohorts, a transient, near complete inhibition of elastase activity was observed after inhalation. In addition, in some patients in the 40 mg QD cohort, a constant level of near complete inhibition gradually developed over the 28 days of drug inhalation. The results from the safety analyses and the confirmed effect on the hNE biomarker by lonodelestat are very encouraging for further development in CF and other inflammatory lung diseases and have established a safe dose regimen. The findings from this study will be taken into account in the design of future studies. “This study provides promising data on the safety of lonodelestat and its potential to inhibit elastase in cystic fibrosis and maybe other chronic inflammatory conditions of the lung where neutrophils play a prominent role in the disease process,” said Marcus Mall, MD, Professor and Head of Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine at the Charité-Universitätsmedizin Berlin. “The landscape of treatment options for patients with cystic fibrosis has changed in the recent years with the approval of new drugs, but there is still a medical need for drugs like lonodelestat that counteract the chronic inflammation and degradation of lung tissue which contributes to pulmonary exacerbations. Lonodelestat may add a new treatment modality for CF patients and I am very excited about the future development of lonodelestat and the next study.” “We are very much encouraged by the trial results which support the hypothesis that lonodelestat may possess properties to counteract underlying inflammatory processes and which indicate treatment was well tolerated in patients with CF. This demonstrates for the first time that complete inhibition of neutrophil elastase can be achieved over a prolonged treatment duration by local delivery through inhalation. We would like to thank the patients, the investigators and their study teams for their participation in this study,” said Dario Eklund, CEO of Santhera. “After additional analyses of the results, we will be optimizing the further clinical development program to advance lonodelestat for the treatment of CF. In parallel, we are proactively pursuing collaborations with partners to assess and exploit the potential of lonodelestat in other pulmonary diseases” References: [1] Sellier Kessler O et al. Effect of POL6014, a potent and selective inhaled neutrophil elastase inhibitor, in a rat model of lung neutrophil activation. Am J Respir Crit Care Med 2018; 197: A2988[2] Lagente V et al. A novel protein epitope mimetic (PEM) neutrophil elastase (NE) inhibitor, POL6014, inhibits human NE-Induced acute lung injury in mice. Am J Respir Crit Care Med 2009; 179: A5668 [3] Barth P et al. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. J Cyst Fibros 2020; 19: 299-304 About lonodelestat Lonodelestat (previously known as POL6014), a highly potent and selective peptide inhibitor of human neutrophil elastase (hNE), is in development for the treatment of cystic fibrosis. Santhera obtained the worldwide, exclusive rights from Polyphor AG to develop and commercialize lonodelestat in CF and other diseases. In preclinical studies lonodelestat was effective in animal models of neutrophil activation in lung tissue and of acute lung injury (ALI) [1, 2]. Currently available clinical data demonstrated that single and multiple doses (Phase 1b) of lonodelestat when administered by inhalation via an optimized eFlow® nebulizer (PARI Pharma GmbH) can lead to high drug concentrations within the lung, resulting in inhibition of hNE in sputum of patients, an enzyme associated with lung tissue inflammation [3]. The Phase 1b study further confirmed the tolerability of lonodelestat after treatment of up to four weeks in patients with CF. Lonodelestat may also show therapeutic benefit for a range of neutrophilic pulmonary diseases with high medical need such as non-CF bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD), chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS) or primary ciliary dyskinesia (PCD). Lonodelestat has EU orphan drug designations (ODD) for the treatment of CF as well as for AATD and PCD in both EU and US. About cystic fibrosis Cystic fibrosis (CF) is a rare, hereditary, life-threatening, progressive disease affecting approximately 70,000 patients in the U.S. and Europe and is characterized by persistent lung infection and chronic inflammation thereby limiting the ability to breathe over time. Activated or necrotic neutrophils liberate human neutrophil elastase (hNE) in the lung that causes damage to structural, cellular and soluble components of the pulmonary microenvironment. High levels of hNE play a central role in the pathophysiology of CF and correlate with disease severity as measured by functional lung parameters. Inhibition of hNE is expected to stop or slow the damage to lung tissue and may help to improve the overall quality of life for individuals with CF. About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com. Raxone® is a trademark of Santhera Pharmaceuticals. For further information please contact: public-relations@santhera.com orEva Kalias, Head External CommunicationsPhone: +41 79 875 27 80eva.kalias@santhera.com Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment 2021 03 01_Lonodelestat_MAD_e_final

  • Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer

    Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer.

  • Mobidiag Receives CE-IVD Marking for Amplidiag® RESP-4 for Simultaneous Detection of COVID-19, Flu A, Flu B and RSV

    CE-IVD marking of Amplidiag RESP-4, molecular diagnostic test for the rapid and simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and RSV

  • Orphazyme appoints Christophe Bourdon as Chief Executive Officer

    Orphazyme A/SCompany announcement No. 05/2021Inside informationCompany Registration No. 32266355 Copenhagen, Denmark, March 1, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced the appointment of Christophe Bourdon as the company’s Chief Executive Officer, effective as of April 1, 2021, following approval from the Board of Directors. Christophe Bourdon has a strong track record in launching and commercializing rare and non-rare disease products in Europe and the United States. He has a deep knowledge of patient journey, market access, and payer dynamics on both sides of the Atlantic. During his 25 years in the biotech/pharmaceutical industry working in three continents and holding several leadership positions, Christophe initiated and accelerated significant strategic transformations and has proven experience building successful multi-cultural and cross-functional teams. He is adept at fostering an environment focused on innovation with one constant driver in mind: Making a meaningful difference for patients. He successfully launched a variety of products in demanding environments, making him an ideal candidate to lead Orphazyme as it prepares for a potential commercial launch of its investigational product candidate, arimoclomol, in the United States and Europe. Christophe Bourdon comes to Orphazyme from his position with Amgen, Inc. as Senior Vice President, General Manager, U.S. Oncology Business, where he led commercialization planning and execution for several products. Prior to Amgen, Christophe was Senior Vice President of Europe, Middle East, Africa, and Canada at Alexion as the company launched two breakthrough ultra-orphan drugs and negotiated payor access across UK, Germany, France, Italy, and Canada. Christophe Bourdon holds an MBA from IMD business school (Switzerland) and a BA from ISG (France). Chairman of the Board of Directors, Georges Gemayel, states “I am delighted to announce Christophe Bourdon will join our leadership team as Chief Executive Officer starting April 1, 2021. This is an important time for Orphazyme, with numerous near-term milestones that will shape the company’s future direction. Our Board conducted an extensive search for a leader who can guide not only our near-term execution, but also align the company around a vision for impact and scale for our long-term growth ambitions. With his strong track record on growth over two decades in relevant roles, Mr. Bourdon will bring his dynamic leadership and skillset to successfully build out and integrate our organization as we prepare for the anticipated commercial launch of our investigational product candidate, arimoclomol, in the United States and Europe. As an authentic and result-oriented leader, he believes in building a transparent and inclusive corporate culture and is the right choice to lead Orphazyme into its next growth phase.” Christophe Bourdon states “The opportunity to join Orphazyme was compelling for me, not only based on its purposeful mission, but also the incredible near-term opportunities to create impact for patients. It is both exciting and humbling to assume this role at such a pivotal time,” said Mr. Bourdon. “Building on the learnings I have gained from my invaluable experience at Amgen and the rare disease experience garnered at Alexion, I look forward to championing this talented team to advance the mission on behalf of our patient communities and deliver value for our shareholders. I am also very much looking forward to relocating to Copenhagen.” For additional information, please contact Orphazyme A/S Anders Vadsholt, Interim CEO and CFO +45 28 98 90 55 About Orphazyme A/S Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis (IBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA). About arimoclomol Arimoclomol is an investigational drug candidate that amplifies the production of Heat-Shock Proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally and has now been studied in seven phase 1, four phase 2 and one pivotal phase 2/3 trial. Arimoclomol is in clinical development for NPC, Gaucher Disease, sIBM, and ALS. Arimoclomol has received orphan drug designation (ODD) for NPC, IBM, and ALS in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC, IBM and ALS. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC. About NPCNiemann-Pick disease Type C (NPC) is a rare, genetic, progressively debilitating, and often fatal neurovisceral disease. It belongs to a family known as lysosomal storage diseases and is caused by mutations leading to defective NPC protein. As a consequence, lipids that are normally cleared by the lysosome accumulate in tissues and organs, including the brain, and drive the disease pathology. We estimate the incidence of NPC to be one in 100,000 live births and the number of NPC patients in the United States and in Europe to be approximately 1,800 individuals. There are no approved treatments for NPC in the U.S. Forward-looking statement This company announcement may contain certain forward-looking statements, including in respect of the anticipated commercialization of arimoclomol. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements, including the risk that applicable regulatory authorities fail to approve arimoclomol on the anticipated timeline or at all. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Attachment 05-2021 Orphazyme appoints Christophe Bourdon as Chief Executive Officer

  • VGP NV: Voting Rights and Denominator

    Press ReleaseRegulated InformationAntwerp, 1 March 2021– 07.00 a.m. CET In application of Article 15 of the Law of May 2, 2007 on the disclosure of major shareholdings in issuers whose shares are admitted for trading on a regulated market, VGP publishes, by means of a press release and on its website, the total share capital, the total number of securities with voting rights and the total number of voting rights at the latest at the end of each month in which any of these numbers has changed. Situation as at 28 February 2021 Total share capital:EUR 102,640,079.19Total number of securities with voting right:20,583,050Total number of securities with double voting right:9,452,290Total number of voting rights (= denominator):30,035,340 This situation (the denominator) serves as a basis for the notification of major shareholdings by shareholders. In accordance with Article 7:53 of the Code on companies and associations and Article 29 of the Articles of Association, fully paid-up registered shares that have been registered in the share register in the name of the same shareholder for at least two consecutive years grant double voting rights. Dematerialised shares do not benefit from the double voting right. The method used by VGP to calculate the holding period of two consecutive years is the LIFO ("last in, first out") method, i.e.: for the same registered shareholder, the shares that the latter has most recently acquired are the first shares that will be deducted from his total amount of registered shares if he/she transfers shares to a third party. Any share converted into a dematerialised share or the ownership of which is transferred loses the double voting right as from its dematerialisation or entry of its transfer in VGP’s share register. It is therefore important that VGP be kept informed of any transfer of registered shares by the transferor and/or the transferee promptly at the time of each transfer in order to enable VGP to keep its register of registered shares and, consequently, the number of registered shares with double voting rights up to date. ABOUT VGP VGP is a pan-European developer, manager and owner of high-quality logistics and semi-industrial real estate. VGP operates a fully integrated business model with capabilities and longstanding expertise across the value chain. The company has a development land bank (owned or committed) of 7.65 million m² and the strategic focus is on the development of business parks. Founded in 1998 as a family-owned real estate developer in the Czech Republic, VGP with a staff of over 260 employees today owns and operates assets in 12 European countries directly and through several 50:50 joint ventures. As of December 2020, the Gross Asset Value of VGP, including the joint ventures at 100%, amounted to € 3.84 billion and the company had a Net Asset Value (EPRA NAV) of € 1.35 billion. VGP is listed on Euronext Brussels and on the Prague Stock Exchange (ISIN: BE0003878957). Attachment 2021.03.01_VGP_Disclosure Transparency Law_Voting rights and denominator_EN